12/27/2005 11:43:59 AM
SANTA CLARA, Calif. & TAIPEI, Taiwan--(BUSINESS WIRE)--Dec. 26, 2005--Affymetrix Inc. (Nasdaq: AFFX) and Vita Genomics announced today that Affymetrix has granted Vita Genomics and its fully owned subsidiary, Shanghai GeneCore BioTechnologies, non-exclusive access to Affymetrix microarray technology to develop and market in-vitro diagnostic (IVD) tests for Alpha Interferon Treatment response in patients with HBV and HCV, as well as for early onset and allergic asthma in infants and young children. The resulting microarray-based IVD products would provide clinicians with better diagnosis methods and more efficient approaches for treating patients and managing these diseases. As part of the Powered by Affymetrix(TM) program, Vita Genomics is able to incorporate Affymetrix' patented arrays into its molecular diagnostic assays developed to predict drug efficacy prior to treatment and assess risks to facilitate disease prevention.
comments powered by